Abstract
Purpose We have recently demonstrated that dietary nitrate, a source of nitric oxide via the enterosalivary pathway, can improve muscle contractile function in healthy older men and women. Nitrate ingestion has also been shown to reduce blood pressure in some, but not all, studies of older individuals. However, the optimal dose for eliciting these beneficial effects is unknown.
Methods A randomized, double-blind, placebo-controlled crossover study was performed to determine the effects of ingesting 3.3 mL/kg of concentrated beetroot juice (BRJ) containing 0, 200, or 400 µmol/kg of nitrate in nine healthy older subjects (one man, eight women; mean age 70±1 y). Maximal knee extensor power (Pmax) and speed (Vmax) were measured 2 h after BRJ ingestion using isokinetic dynamometry. Blood pressure was monitored periodically throughout each study.
Results Pmax (in W/kg) was higher (P< 0.05) after the low dose (3.9±0.4) compared to the placebo (3.7±0.4) or high dose (3.7±0.4). Vmax (in rad/s) also tended higher (P = 0.08) in the low (11.9±0.7) compared to the placebo (10.8±0.8) or high dose (11.2±0.8) trials. Eight out of nine subjects achieved a higher Pmax and Vmax after the lower vs. the higher dose. These dose-related changes in muscle contractility paralleled changes in nitric oxide (NO) bioavailability, as reflected by changes in breath NO and plasma 3-nitrotyrosine levels. No significant changes were found in systolic, diastolic, or mean arterial pressure.
Conclusions Varying doses of dietary nitrate have differential effects on muscle function and blood pressure in older individuals. A moderate dose of nitrate increases muscle speed and power, but these improvements are lost at a higher dose. Blood pressure, on the other hand, is not reduced even with a higher dose.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03595774
Funding Statement
This work was supported by grants from the Office of the Vice Provost for Research at Indiana University Purdue University Indianapolis and the National Institute on Aging (R21 AG053606) to A.R. Coggan; the National Heart, Lung, and Blood institute (R34 HL138253) to A.R. Coggan and Linda R. Peterson; the National Institute on Diabetes, Digestive, and Kidney Diseases (K23 DK102824) to R.N. Moorthi, the National Institute on Arthritis and Musculoskeletal and Skin Disease (P30 AR072581) to Sharon Mo; and the National Center for Advancing Translational Sciences (UL1 TR002529) to Anantha Shekhar. For the remaining authors no conflicts of interest are declared. The contents of this article are solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health or the American College of Sports Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Subjects Office, Indiana University, protocol 1712606816
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available upon request from corresponding author.
